Regeneration of pancreatic islets in vivo by ultrasound-targeted gene therapy.

Abstract:

:This study uses a novel approach to gene therapy in which plasmid DNA is targeted to the pancreas in vivo using ultrasound-targeted microbubble destruction (UTMD) to achieve islet regeneration. Intravenous microbubbles carrying plasmids are destroyed within the pancreatic microcirculation by ultrasound, achieving local gene expression that is further targeted to β-cells by a modified rat insulin promoter (RIP3.1). A series of genes implicated in endocrine development were delivered to rats 2 days after streptozotocin-induced diabetes. The genes, PAX4, Nkx2.2, Nkx6.1, Ngn3 and Mafa, produced α-cell hyperplasia, but no significant improvement in β-cell mass or blood glucose level 30 days after UTMD. In contrast, RIP3.1-NeuroD1 promoted islet regeneration from surviving β-cells, with normalization of glucose, insulin and C-peptide levels at 30 days. In a longer-term experiment, four of six rats had a return of diabetes at 90 days, accompanied by β-cell apoptosis on Tunel staining. Pretreatment with the JNK inhibitor SP600125 successfully blocked β-cell apoptosis and resulted in restoration of β-cell mass and normalization of blood glucose level for up to 90 days. This technique allows in vivo islet regeneration, restoration of β-cell mass and normalization of blood sugar, insulin and C-peptide in rats without viruses.

journal_name

Gene Ther

journal_title

Gene therapy

authors

Chen S,Shimoda M,Wang MY,Ding J,Noguchi H,Matsumoto S,Grayburn PA

doi

10.1038/gt.2010.85

subject

Has Abstract

pub_date

2010-11-01 00:00:00

pages

1411-20

issue

11

eissn

0969-7128

issn

1476-5462

pii

gt201085

journal_volume

17

pub_type

杂志文章
  • Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.

    abstract::We constructed a melanoma-specific oncolytic adenoviral vector Ad.MCDIRESE1.71Hsp3, in which the cytosine deaminase and adenoviral E1A genes linked by the IRES sequence were under the control of a mouse tyrosinase enhancer/promoter transcriptional element in the E1 region of the vector. We also inserted the human heat...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302776

    authors: Liu Y,Ye T,Sun D,Maynard J,Deisseroth A

    更新日期:2006-08-01 00:00:00

  • Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression.

    abstract::Polynucleotide immunization has been employed as a means of inducing immune responses through the introduction of antigen-encoding DNA. While immunization against specific tumor antigens may be achieved through this strategy, various candidate tumor antigens may not be approached via DNA-based vaccines as they represe...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300423

    authors: Strong TV,Hampton TA,Louro I,Bilbao G,Conry RM,Curiel DT

    更新日期:1997-06-01 00:00:00

  • Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.

    abstract::Viral gene vectors often rely on packaging cell lines, which provide the necessary factors in trans for the formation of virus-like particles. Previously, we reported on a first-generation packaging cell line for gene vectors, which are based on the B-lymphotropic Epstein-Barr virus (EBV), a human gamma-herpesvirus. T...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302714

    authors: Hettich E,Janz A,Zeidler R,Pich D,Hellebrand E,Weissflog B,Moosmann A,Hammerschmidt W

    更新日期:2006-05-01 00:00:00

  • Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava.

    abstract::Hydrodynamic gene delivery is an attractive option for non-viral liver gene therapy, but requires evaluation of efficacy, safety and clinically applicable techniques in large animal models. We have evaluated retrograde delivery of DNA to the whole liver via the isolated segment of inferior vena cava (IVC) draining the...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3303079

    authors: Fabre JW,Grehan A,Whitehorne M,Sawyer GJ,Dong X,Salehi S,Eckley L,Zhang X,Seddon M,Shah AM,Davenport M,Rela M

    更新日期:2008-03-01 00:00:00

  • Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model.

    abstract::Exogenous osteoprotegerin (OPG) gene modification appears a therapeutic strategy for osteolytic aseptic loosening. The feasibility and efficacy of a cell-based OPG gene delivery approach were investigated using a murine model of knee prosthesis failure. A titanium pin was implanted into mouse proximal tibia to mimic a...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.64

    authors: Zhang L,Jia TH,Chong AC,Bai L,Yu H,Gong W,Wooley PH,Yang SY

    更新日期:2010-10-01 00:00:00

  • On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids.

    abstract::The mechanism whereby cationic lipids destabilize cell membranes to facilitate the intracellular delivery of macromolecules such as plasmid DNA or antisense oligonucleotides is not well understood. Here, we show that cationic lipids can destabilize lipid bilayers by promoting the formation of nonbilayer lipid structur...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301506

    authors: Hafez IM,Maurer N,Cullis PR

    更新日期:2001-08-01 00:00:00

  • Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors.

    abstract::Human pluripotent stem cell-derived neural progenitor (hNP) cells are an excellent resource for understanding early neural development and neurodegenerative disorders. Given that many neurodegenerative disorders can be correlated with defects in the mitochondrial genome, optimal utilization of hNP cells requires an ab...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.134

    authors: Iyer S,Xiao E,Alsayegh K,Eroshenko N,Riggs MJ,Bennett JP Jr,Rao RR

    更新日期:2012-05-01 00:00:00

  • High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.

    abstract::Mucopolysaccharidosis type IIIA (MPS-IIIA) or Sanfilippo A syndrome is a lysosomal storage genetic disease that results from the deficiency of the N-sulfoglucosamine sulfohydrolase (SGSH) protein, a sulfamidase required for the degradation of heparan sulfate glycosaminoglycans (GAGs). The accumulation of these macromo...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2014.75

    authors: Quiviger M,Arfi A,Mansard D,Delacotte L,Pastor M,Scherman D,Marie C

    更新日期:2014-12-01 00:00:00

  • Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors.

    abstract::Transplantation of allogeneic pancreatic islets is an effective approach to treat type 1 diabetes. To bypass the need for systemic administration of immunosuppression drugs following transplantation, approaches to genetically modify allogeneic islets to express anti-inflammatory, immunosuppressive, or antiapoptotic pr...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302530

    authors: Rehman KK,Wang Z,Bottino R,Balamurugan AN,Trucco M,Li J,Xiao X,Robbins PD

    更新日期:2005-09-01 00:00:00

  • B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.

    abstract::Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. A CAR strategy can target any tumor surface antigens as long as an antigen-binding receptor can be generated. New CARs that target solid tumors and have t...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2015.29

    authors: Wu MR,Zhang T,DeMars LR,Sentman CL

    更新日期:2015-08-01 00:00:00

  • Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.

    abstract::Isolated limb perfusion (ILP) is a limb salvage surgical modality used to deliver chemotherapy and biologic agents to locally advanced and recurrent extremity soft tissue sarcoma (STS), and may be readily tailored for delivery of gene therapy. We set out to test the feasibility of delivering AdFLAGp53 (replication inc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302911

    authors: Hannay J,Davis JJ,Yu D,Liu J,Fang B,Pollock RE,Lev D

    更新日期:2007-04-01 00:00:00

  • Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.

    abstract::Advanced prostate cancer (PC) still remains incurable. Novel immunogene therapy shows promise as treatment strategy that can target both localized and metastasized PC. In this study, we have developed a PC-specific oncolytic adenovirus (Ad-PL-PPT-E1A) armed with fusion gene of prostate-specific antigen and CD40 ligand...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2014.46

    authors: Yang YF,Xue SY,Lu ZZ,Xiao FJ,Yin Y,Zhang QW,Wu CT,Wang H,Wang LS

    更新日期:2014-08-01 00:00:00

  • Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.

    abstract::Solid tumors meet their demands for nascent blood vessels and increased glycolysis, to combat hypoxia, by activating multiple genes involved in angiogenesis and glucose metabolism. Hypoxia inducible factor-1 (HIF-1) is a constitutively expressed basic helix-loop-helix transcription factor, formed by the assembly of HI...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301388

    authors: Sun X,Kanwar JR,Leung E,Lehnert K,Wang D,Krissansen GW

    更新日期:2001-04-01 00:00:00

  • Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

    abstract::Adeno-associated virus (AAV) gene therapy constitutes a powerful tool for the treatment of neurodegenerative diseases. While AAVs are generally administered systemically to newborns in preclinical studies of neurological disorders, in adults the maturity of the blood-brain barrier (BBB) must be considered when selecti...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2017.18

    authors: Bey K,Ciron C,Dubreil L,Deniaud J,Ledevin M,Cristini J,Blouin V,Aubourg P,Colle MA

    更新日期:2017-05-01 00:00:00

  • Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells.

    abstract::Hypoxia initiates an adaptive physiological response in all organisms and plays a role in the pathogenesis of several human diseases. The hypoxia/HIF-inducible factor-1 (HIF-1) transcription factor mediates transcriptional responses to hypoxia by binding to a cis-acting hypoxia-responsive element (HRE) present within ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301605

    authors: Post DE,Van Meir EG

    更新日期:2001-12-01 00:00:00

  • Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model.

    abstract::Mucopolysaccharidosis type I (MPSI) is an autosomic recessive, lysosomal storage disorder due to the deficit of the enzyme α-L-iduronidase (IDUA). The disease accounts for a general impairment of tissue and organ functions, mainly including heart disease, corneal clouding, organomegaly, skeletal malformations and join...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2011.94

    authors: Piller Puicher E,Tomanin R,Salvalaio M,Friso A,Hortelano G,Marin O,Scarpa M

    更新日期:2012-04-01 00:00:00

  • Targeting of cell receptors and gene transfer efficiency: a balancing act.

    abstract::Vectors conjugated with ligands recognized by cell surface receptors are of interest for cystic fibrosis gene therapy since these vectors would allow cell-specific targeting. However, an efficient and specific uptake may be abrogated by a subsequent intracellular trafficking leading to an inefficient gene transfer. Th...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301738

    authors: Fajac I,Grosse S,Briand P,Monsigny M

    更新日期:2002-06-01 00:00:00

  • Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.

    abstract::Newly isolated serotypes of AAV readily cross the endothelial barrier to provide efficient transgene delivery throughout the body. However, tissue-specific expression is preferred in most experimental studies and gene therapy protocols. Previous efforts to restrict gene expression to the myocardium often relied on dir...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.105

    authors: Prasad KM,Xu Y,Yang Z,Acton ST,French BA

    更新日期:2011-01-01 00:00:00

  • Expression of the human glucocerebrosidase and arylsulfatase A genes in murine and patient primary fibroblasts transduced by an adeno-associated virus vector.

    abstract::We have constructed two recombinant adeno-associated virus (AAV) vectors (pJJ-3GC and pJJ-3ASA) which contained either the human glucocerebrosidase (GC) or arylsulfatase A (ASA) cDNA under the control of an SV40 promoter. These plasmids were co-transfected to 293 cells with a helper plasmid containing trans-acting AAV...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:

    authors: Wei JF,Wei FS,Samulski RJ,Barranger JA

    更新日期:1994-07-01 00:00:00

  • Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

    abstract::A fully intact immune system would be expected to hinder the efficacy of oncolytic virotherapy by inhibiting viral replication. Simultaneously, however, it may also enhance antitumor therapy through initiation of proinflammatory, antiviral cytokine responses at the tumor site. The aim of this study was to investigate ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.161

    authors: Galivo F,Diaz RM,Wongthida P,Thompson J,Kottke T,Barber G,Melcher A,Vile R

    更新日期:2010-02-01 00:00:00

  • In vivo targeted delivery of CD40 shRNA to mouse intestinal dendritic cells by oral administration of recombinant Sacchromyces cerevisiae.

    abstract::Short hairpin RNA (shRNA)-mediated gene regulation is a commonly used technique for gene manipulation. An efficient and safe delivery system is indispensable when shRNA is delivered into living organisms for gene therapy. Previous studies have proved that DNA and protein can be delivered into dendritic cells (DCs) by ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2014.50

    authors: Zhang L,Zhang T,Wang L,Shao S,Chen Z,Zhang Z

    更新日期:2014-07-01 00:00:00

  • Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.

    abstract::For patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need for novel therapies and improvement of existing modalities. We propose that p53 gene therapy and chemotherapy, when combined, will provide superior tumor cell killing for the treatment of prostate carcinoma. To this end, we ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41434-019-0071-x

    authors: Tamura RE,Lana MG,Costanzi-Strauss E,Strauss BE

    更新日期:2020-02-01 00:00:00

  • Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach.

    abstract::The growth and metastasis of solid tumors relies on the activities of polypeptide growth factors to recruit stromal tissue and expand the tumor mass. Pleiotrophin (PTN) is a secreted growth factor with angiogenic activity that has been found to contribute to the growth and metastasis of tumors including melanoma. Here...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302398

    authors: Malerczyk C,Schulte AM,Czubayko F,Bellon L,Macejak D,Riegel AT,Wellstein A

    更新日期:2005-02-01 00:00:00

  • An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.

    abstract::Current experimental gene therapy approaches for Parkinson's disease (PD) and dementia with Lewy bodies (DLB) include the use of viral vectors expressing antiapoptosis genes, neurotrophic factors and dopaminergic system enzymes. However, since increasing evidence favors a role for alpha-synuclein accumulation in the p...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3302349

    authors: Hashimoto M,Rockenstein E,Mante M,Crews L,Bar-On P,Gage FH,Marr R,Masliah E

    更新日期:2004-12-01 00:00:00

  • Stabilized plasmid-lipid particles for systemic gene therapy.

    abstract::The structure of 'stabilized plasmid-lipid particles' (SPLP) and their properties as systemic gene therapy vectors has been investigated. We show that SPLP can be visualized employing cryo-electron microscopy to be homogeneous particles of diameter 72 +/- 5 nm consisting of a lipid bilayer surrounding a core of plasmi...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301308

    authors: Tam P,Monck M,Lee D,Ludkovski O,Leng EC,Clow K,Stark H,Scherrer P,Graham RW,Cullis PR

    更新日期:2000-11-01 00:00:00

  • Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein.

    abstract::T-cell dysfunction is thought to be central to the immunodeficiency state seen in patients with the Wiskott-Aldrich syndrome (WAS). Aspects of the WAS phenotype have been corrected in other cell types on introduction of the normal WAS protein (WASP), but the potential for correction of the T-cell defects has not been ...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3301950

    authors: Strom TS,Gabbard W,Kelly PF,Cunningham JM,Nienhuis AW

    更新日期:2003-05-01 00:00:00

  • Expression of beta-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system.

    abstract::Sindbis virus expression has been used for in vitro investigations of antigen processing, presentation and epitope mapping. The recent development of a replication-deficient recombinant Sindbis virus expression vector has made in vivo expression possible with minimal pathogenic risk. Advantages of Sindbis virus over o...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300458

    authors: Altman-Hamamdzic S,Groseclose C,Ma JX,Hamamdzic D,Vrindavanam NS,Middaugh LD,Parratto NP,Sallee FR

    更新日期:1997-08-01 00:00:00

  • Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid.

    abstract::Adenovirus (Ad)-mediated delivery of anti-angiogenic molecules into tumors constitutes an appealing approach for growth inhibition. However, lack of expression on tumors of Ad receptors leads to weak tumor transduction. Therefore, to provide Ad with a new entry pathway into tumors, an NGR peptide was inserted into eit...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2009.97

    authors: Jullienne B,Vigant F,Muth E,Chaligné R,Bouquet C,Giraudier S,Perricaudet M,Benihoud K

    更新日期:2009-12-01 00:00:00

  • Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.

    abstract::Persistence of human immunodeficiency virus (HIV) despite highly active antiretroviral therapy (HAART) is a lasting challenge to virus eradication. To develop a strategy complementary to HAART, we constructed a series of Rev-dependent lentiviral vectors carrying diphtheria toxin A chain (DT-A) and its attenuated mutan...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/gt.2010.53

    authors: Wang Z,Tang Z,Zheng Y,Yu D,Spear M,Iyer SR,Bishop B,Wu Y

    更新日期:2010-09-01 00:00:00

  • Use of protamine to augment adenovirus-mediated cancer gene therapy.

    abstract::Improving the therapeutic potential of adenoviral (Ad) suicide gene therapy has become an area of intense investigation since the inception of gene therapy strategies for cancer treatment. Poor efficiency of gene transfer to target tissues has become one of the most important limitations to Ad-based gene therapy. Sinc...

    journal_title:Gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.gt.3300987

    authors: Lanuti M,Kouri CE,Force S,Chang M,Amin K,Xu K,Blair I,Kaiser L,Albelda S

    更新日期:1999-09-01 00:00:00